12.63

1.57% -0.12

Novocure Ltd (NVCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NVCR? Forum Prognose

Schlusskurs vom Vortag:

$12.75

Offen:

$12.57

24-Stunden-Volumen:

36,348

Relative Volume:

0.02

Marktkapitalisierung:

$1.43B

Einnahmen:

$655.35M

Nettoeinkommen (Verlust:

$-136.23M

KGV:

-10.33

EPS:

-1.2223

Netto-Cashflow:

$-75.68M

1W Leistung:

-6.48%

1M Leistung:

+19.52%

6M Leistung:

-1.41%

1J Leistung:

-41.14%

1-Tages-Spanne:

$12.51

$12.74

1-Wochen-Bereich:

$12.45

$14.33

52-Wochen-Spanne:

$9.82

$21.55

Novocure Ltd Stock (NVCR) Company Profile

Firmenname

Novocure Ltd

Sektor

Healthcare (1117)

Branche

Medical Devices (139)

Telefon

44 (0)15 3475 6700

Adresse

NO. 4 THE FORUM, ST. HELIER

Mitarbeiter

1,605

Twitter

@novocure

Nächster Verdiensttermin

2026-04-23

Neueste SEC-Einreichungen

NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVCR Novocure Ltd	12.59	1.47B	655.35M	-136.23M	-75.68M	-1.2223
ABT Abbott Laboratories	110.10	192.10B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	356.68	137.25B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	89.82	115.41B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	69.73	103.81B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	85.36	49.82B	6.07B	1.06B	1.34B	1.8063

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-25	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-07-08	Eingeleitet	Ladenburg Thalmann	Buy
2024-12-02	Hochstufung	Evercore ISI	In-line → Outperform
2024-10-16	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-08	Hochstufung	Piper Sandler	Neutral → Overweight
2023-08-04	Eingeleitet	SVB Securities	Outperform
2023-07-31	Hochstufung	Evercore ISI	Underperform → In-line
2023-06-07	Hochstufung	Wedbush	Underperform → Neutral
2023-05-16	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-17	Herabstufung	JP Morgan	Neutral → Underweight
2023-01-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-01-05	Bestätigt	H.C. Wainwright	Buy
2022-11-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-24	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-05	Herabstufung	Evercore ISI	In-line → Underperform
2022-05-16	Eingeleitet	H.C. Wainwright	Buy
2022-02-08	Eingeleitet	Loop Capital	Buy
2022-02-02	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-20	Hochstufung	Truist	Hold → Buy
2022-01-03	Hochstufung	Evercore ISI	Underperform → In-line
2021-07-01	Herabstufung	Mizuho	Buy → Neutral
2021-04-14	Herabstufung	Wedbush	Neutral → Underperform
2021-01-25	Bestätigt	Piper Sandler	Overweight
2020-09-23	Eingeleitet	Northland Capital	Outperform
2020-09-18	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-09-17	Herabstufung	Truist	Buy → Hold
2020-06-01	Fortgesetzt	Oppenheimer	Perform
2020-05-01	Herabstufung	Oppenheimer	Outperform → Perform
2020-04-09	Herabstufung	Evercore ISI	In-line → Underperform
2020-03-05	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-29	Hochstufung	SunTrust	Hold → Buy
2019-07-26	Herabstufung	JP Morgan	Overweight → Neutral
2019-07-26	Herabstufung	Wedbush	Outperform → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2018-11-02	Herabstufung	Wells Fargo	Outperform → Market Perform
2018-07-16	Eingeleitet	Evercore ISI	Outperform
2018-04-18	Bestätigt	Mizuho	Buy
2018-02-23	Bestätigt	Mizuho	Buy
2017-05-24	Hochstufung	Wells Fargo	Market Perform → Outperform
2016-07-29	Bestätigt	Wedbush	Outperform
2016-01-19	Eingeleitet	Barclays	Underweight
2015-12-02	Eingeleitet	Deutsche Bank	Hold

Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

Mar 10, 2026

Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com India

Mar 10, 2026

Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia

Mar 10, 2026

Mar 09, 2026

Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - simplywall.st

Mar 09, 2026

Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance

Mar 09, 2026

Mar 06, 2026

Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm

Mar 06, 2026

NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 06, 2026

Mar 05, 2026

NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat

Mar 05, 2026

NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat

Mar 05, 2026

Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat

Mar 05, 2026

Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan

Mar 03, 2026

NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan

Mar 03, 2026

Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan

Mar 03, 2026

NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan

Mar 03, 2026

NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm

Mar 03, 2026

FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News

Mar 03, 2026

Mar 02, 2026

Novocure gains Japan reimbursement for Optune Lua device - Investing.com Australia

Mar 02, 2026

NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha

Mar 02, 2026

NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union

Mar 02, 2026

NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance

Mar 02, 2026

Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus

Mar 02, 2026

Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus

Mar 02, 2026

Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com Canada

Mar 02, 2026

Japan’s health system to cover wearable lung cancer device Optune Lua - Stock Titan

Mar 02, 2026

Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat

Mar 02, 2026

A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance

Mar 02, 2026

Mar 01, 2026

NovoCure Earnings Call: Growth Builds Amid Profit Strain - TipRanks

Mar 01, 2026

NovoCure Ltd. Opens with 6.47% Gain, Outpacing S&P 500's 0.69% Rise - Markets Mojo

Mar 01, 2026

NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo

Mar 01, 2026

NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo

Mar 01, 2026

NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo

Mar 01, 2026

Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st

Mar 01, 2026

Feb 28, 2026

NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st

Feb 28, 2026

Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR - MarketBeat

Feb 28, 2026

Feb 27, 2026

Novocure CEO and CFO to field investor questions at Leerink event - Stock Titan

Feb 27, 2026

NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 27, 2026

Novocure to Participate in 2026 Leerink Global Healthcare Conference - Yahoo Finance

Feb 27, 2026

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus

Feb 27, 2026

Feb 26, 2026

NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat

Feb 26, 2026

NovoCure (NVCR) Q4 Loss Narrowing Challenges Bearish Narrative On Persistent Unprofitability - simplywall.st

Feb 26, 2026

NovoCure: Q4 Earnings Snapshot - theheraldreview.com

Feb 26, 2026

NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Feb 26, 2026